Stock fact sheet · data as of
Alkermes plc (ALKS): fair value, margin of safety and Wheel Score
Ticker symbol ALKS · Healthcare · Drug Manufacturers - Specialty & Generic · Ireland · Speculative
Is ALKS undervalued?
At 45.89 (close of 5 Nov 2026), ALKS trades 30% over the GLS average fair value of 35.37. 0 of the 2 models land above the price and 2 below. A negative margin of safety fails the "below fair value" Wheel Trade Filter - the models see no discount, which does not make the business a poor one, only the price a full one.
The average is built from just 2 models (DCF, 10 Cap) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.
The nightly engine files ALKS under Speculative - it is losing money or its Piotroski health score is 3 or lower - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for ALKS
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 37.16 | -19% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | 33.58 | -27% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | 7.26 | -84% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 58.70 | +28% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Alkermes plc scores only 2 of 9 on the Piotroski F-score, which fails the "Piotroski 6 or more" Wheel Trade Filter. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. On durability ALKS scores 6.0/10 on the GLS Moat - a middle reading; the Moat Score tab on the Quote page's Financials view shows which of the four parts hold it back.
Returns on capital are high - ROIC 12.8%, ROE 13.3%, ROA 9.6% - with debt at 0.04 times equity and a free-cash-flow yield of 3.0%.
Alkermes plc pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Product 57%, Vivitrol 17%, Aristada And Aristada Initio 13% (quarter Q2 FY2026).
Institutional ownership scores 10/10, insider activity 3/10 and Congressional trading 10/10 on the GLS smart-money scales; the last recorded Congressional buy was on 29 Sep 2026.
| Piotroski F-score | 2 / 9 | ROIC | 12.8% |
|---|---|---|---|
| GLS Moat | 6.0 / 10 | ROE | 13.3% |
| Debt / equity | 0.04 | ROA | 9.6% |
| Free-cash-flow yield | 3.0% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 3 · 10 / 10 |
Wheel Score 33: Weak
With a Wheel Score of 33 Alkermes plc sits in the Weak band. It fails filter 2, a real business, not a gamble - speculative (a loss, or a weak Piotroski score); and filter 3, below fair value - trades 30% above our fair value; and filter 4, financially healthy - Piotroski 2/9 (under 6); Value (weak) is its weakest part.
Implied volatility is 47% on the near-the-money contracts 20-60 days out - inside the 35-60% sweet spot the Wheel Score rewards most: enough premium to be worth selling, not so much that the risk is unpaid. Chain open interest is 15,438 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 2.2M shares a day on a market cap of $7.7B, with a beta of 0.27 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score rates that good.
| Filter | Wheel Trade Filter | Result | Detail |
|---|---|---|---|
| 1 | Options that actually trade | Passes | Listed options with 1,000+ contracts of open interest and 100+ traded a day |
| 2 | A real business, not a gamble | Fails | speculative (a loss, or a weak Piotroski score) |
| 3 | Below fair value | Fails | trades 30% above our fair value |
| 4 | Financially healthy | Fails | Piotroski 2/9 (under 6) |
| 5 | Can repay its debt | Passes | Long-term debt repaid from 3 years of operating cash flow or less (6 for real estate and utilities; banks and insurers are not judged on it) |
| 6 | No serious red flags | Passes | Red Flags score 60 or more out of 100 (earnings, margins, debt, analysts, filings and price checked the same way for every stock) |
| 7 | A premium worth selling | Passes | Implied volatility 25-80% (enough premium, not a lottery ticket) |
| 8 | Big enough | Passes | Market cap $1 billion or more |
| 9 | Not a penny stock | Passes | Share price $5 or more |
| How it ranks | Rating | From | |
|---|---|---|---|
| Value | Weak | 30% above fair value | |
| Premium | Strong | implied volatility 47% | |
| Moat | Good | moat 6.0/10 | |
| Health | Weak | Piotroski 2/9 | |
| Red Flags | Fair | Red Flags score 70/100 | |
| Option trading | Fair | 854 contracts a day, 15,438 open interest | |
| Stability | Good | beta 0.27, $7.7B company |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls: a stock must pass all 9 Wheel Trade Filters to score 70, and the score then ranks the ones that pass; the Sunday Scan is the top 10. It is updated nightly and is not a recommendation. How the Wheel Score works · the walkthrough lesson shows how it fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for ALKS in the nightly calendar.
No analyst upgrades or downgrades were recorded in the last 30 days.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - Specialty & Generic
The 12 companies below are the closest to Alkermes plc by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| AMRX Amneal Pharmaceuticals, Inc. | 19.95 | 10.56 | -89% | 35Weak | $6.9B |
| LNTH Lantheus Holdings, Inc. | 101.14 | 191.29 | +47% | 39Weak | $6.6B |
| RDY Dr. Reddy's Laboratories Limited | 14.77 | 8.03 | -84% | 34Weak | $12.3B |
| ELAN Elanco Animal Health Incorporated | 25.31 | 11.44 | -121% | 36Weak | $12.6B |
| BHC Bausch Health Companies Inc. | 8.34 | 145.40 | +94% | 53Fair | $3.1B |
| RGC Regencell Bioscience Holdings Limited | 5.42 | 0.0281 | -19191% | 8Weak | $2.7B |
| VTRS Viatris Inc. | 19.22 | 19.02 | -1% | 39Weak | $22.1B |
| HCM HUTCHMED (China) Limited | 13.92 | 2.86 | -386% | 31Weak | $2.4B |
| PRGO Perrigo Company plc | 15.83 | 47.02 | +66% | 44Weak | $2.2B |
| TRLV Trulieve Cannabis Corp. | 11.60 | 25.12 | +54% | 30Weak | $2.0B |
| ALVO Alvotech | 4.67 | - | - | 14No options | $1.7B |
| ANIP ANI Pharmaceuticals, Inc. | 71.65 | 251.58 | +72% | 49Weak | $1.6B |
Scan the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the top 10 stocks that pass all 9 Wheel Trade Filters, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about ALKS
Is ALKS undervalued right now?
No: at 45.89 the stock trades 30% above the GLS average fair value of 35.37 (data as of 5 Nov 2026). The margin of safety is negative.
What is the Wheel Score of ALKS and what does it mean?
ALKS scores 33 out of 100 (Weak) - it fails Wheel Trade Filters 2, 3, 4. The Wheel Score ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned - in two parts: the 9 pass/fail Wheel Trade Filters (busy options, a real business, below fair value, Piotroski 6 or more, debt it can repay, a Red Flags score of 60 or more, implied volatility of 25-80%, a $1 billion company, $5 a share) and a ranking of how strongly a stock passes on value, premium, moat, health, red flags, option trading and stability. A stock that fails any filter stays under 70; 70-84 is Good, 85 and above is Prime. The Sunday Scan is the top 10 that pass, sorted by Wheel Score.
What is the GLS fair value for ALKS?
35.37 per share as of 5 Nov 2026 - the simple average of the 2 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Alkermes plc report earnings next?
No upcoming earnings date is recorded for ALKS in our calendar as of 5 Nov 2026; the Calendars page is refreshed every morning.
Does ALKS have listed options, and how liquid are they?
Yes. The nightly snapshot found 138 listed contracts with 15,438 open interest across all expiries and implied volatility of 47% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.